742 reports of this reaction
2.7% of all BICALUTAMIDE reports
#6 most reported adverse reaction
PROSTATE CANCER is the #6 most commonly reported adverse reaction for BICALUTAMIDE, manufactured by ANI Pharmaceuticals, Inc.. There are 742 FDA adverse event reports linking BICALUTAMIDE to PROSTATE CANCER. This represents approximately 2.7% of all 27,404 adverse event reports for this drug.
Patients taking BICALUTAMIDE who experience prostate cancer should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PROSTATE CANCER is a less commonly reported adverse event for BICALUTAMIDE, but still significant enough to appear in the safety profile.
In addition to prostate cancer, the following adverse reactions have been reported for BICALUTAMIDE:
The following drugs have also been linked to prostate cancer in FDA adverse event reports:
PROSTATE CANCER has been reported as an adverse event in 742 FDA reports for BICALUTAMIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
PROSTATE CANCER accounts for approximately 2.7% of all adverse event reports for BICALUTAMIDE, making it a notable side effect.
If you experience prostate cancer while taking BICALUTAMIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.